Hospira's Angiomax Generic At Risk As Contract Manufacturing Gets Legal Reprieve
Executive Summary
Federal Circuit en banc court reverses panel decision, giving The Medicines Company chance to prove infringement and get Hospira's generic off the market.
You may also be interested in...
Angiomax Patent Dispute: On-Sale Bar Applies To Distribution Agreement
Hospira's generic does not infringe The Medicine Company's patented method of making Angiomax, US Federal Circuit finds, but leaves question of whether TMC's distribution agreement covers manufacturing process for the district court to decide.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.